Paul Sondel and Amy Erbe-Gurel receive U01 subaward to study neuroblastoma vaccines

Paul Sondel, MD, PhD, professor, Division of Hematology, Oncology, and Bone Marrow Transplant, and Amy Erbe-Gurel, PhD, senior scientist III in the Sondel Lab, are recent subaward recipients of a National Institutes of Health (NIH) U01 grant. Sondel and Erbe-Gurel will work alongside John Maris, MD, of Children’s Hospital of Philadelphia (CHOP). That hospital will serve as the primary site for the study. The project, entitled “Personalized Neuroblastoma Vaccines,” aims to achieve improved outcomes for patients with high-risk neuroblastoma through the development of a personalized vaccination strategy targeting the individualized validated neoantigens. High-risk neuroblastoma is a cancer that arises from the developing sympathetic nervous system. It remains lethal in 50% of patients despite intensive multi-modal therapy. Sondel is a principal investigator on the project and Erbe-Gurel will serve as a co-investigator. The subaward, in the amount of $70,834 over five years, is slated to begin soon and will run through 2028.